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During the present coronavirus 2019 (COVID-19) pan-
demic, a wide range of experimental treatments have been
offered on a wide scale to treat severe cases of COVID-19
– often using off-label regimens with well-established
safety profiles that were licensed for other indications,
such as lopinavir-ritonavir [1, 2]. Meanwhile, after pre-
liminary results from the “Adaptive COVID-19 Treatment
Trial”, the experimental drug remdesivir has received an
emergency use authorisation by the US Food and Drug Ad-
ministration. These recent decisions exhibit the pressure on
regulatory agencies and healthcare professionals to make
off-label treatments available during pandemics. A liberal
approach to off-label treatment, however, has been criti-
cised, as these treatments should first be evaluated in ran-
domised controlled trials with adequate clinical endpoints
prior to their widespread application for novel indications
[3].
During pandemics, many healthcare workers may be hesi-
tant to offer experimental treatments. The reasons are well
grounded on the principles of evidence-based medicine
and bioethics as we, healthcare professionals, live by the
principle to first, do no harm, second, be careful, and third,
heal (primum non nocere, secundum cavere, tertium
sanare). Under some circumstances, healthcare workers’
and health policy makers’ decisions may be biased towards
primum non nocere as they may tend to overestimate risks
while underestimating the potential benefits of rapid initia-
tion of experimental treatment; this may well also occur in
the other direction, with underestimation of risks and over-
estimation of benefits – shifting decisions towards primum
sanare. Therefore, off-label treatment decisions should be
based on careful, preliminary estimations of the harm-ben-
efit balance, to avoid passive and active harm to the pa-
tient.
Modelling harm-benefit for off-label drugs
In figure 1, we have modelled a range of harm-benefit
curves for off-label drugs with diverse efficacy and safety
profiles in the treatment of infectious diseases caused by
an unspecified pathogen. This could likely represent severe
acute respiratory syndrome coronavirus 2, with a sharp in-
crease in case fatality ratios for higher age groups (as de-
picted with age bands). This hypothetical example illus-
trates that some scenarios could result in net beneficial
effects (harm-benefit ratio <1) of off-label treatments in
patients with various case fatality ratios. In the end, harm-
benefit ratios will be influenced by the case fatality ratio as
well as the clinical efficacy and safety profile of an off-la-
bel drug regimen. If the relative risk reduction of all-cause
mortality is small, then only those with higher case fatal-
ity may benefit sufficiently to outweigh the risk of seri-
ous adverse events. For COVID-19, a high case fatality
has been observed in some cohorts despite early treatment
with off-label drugs. Importantly, the first randomised con-
trolled trials in COVID-19 patients showed no beneficial
effects of certain off-label treatments compared with place-
bo. This may indicate that the expected clinical efficacy of
these specific off-label drugs is limited (or absent) – shift-
ing the harm-benefit curve to the right, towards higher case
fatality ratios. These high-risk populations may, however,
be disproportionally affected by drug-drug interactions, se-
rious adverse events and comorbidities, which may com-
plicate and argue against off-label treatment initiation.
Decisions on off-label treatment use during
pandemics
We have learned from previous instances in medical histo-
ry that thorough clinical evaluation of off-label treatments
are essential to protect patients’ welfare. A the same time,
during large outbreaks and pandemics with highly path-
ogenic infectious agents without licensed treatment op-
tions, healthcare professionals may have to decide quickly
whether off-label drug regimens could be offered to pa-
tients at high risk. In such emergency situations and given
a high case fatality ratio in patient sub-groups and an ac-
ceptable safety profile of the experimental drug regimens
under consideration for their approved indications, we rea-
son that rapid off-label treatment initiation may be consid-
ered from the outset for patients at high risk, under cer-
tain conditions. This approach should be implemented in
an internationally coordinated trial setting, which can be
outlined in advance for future pandemics, and by following
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Figure 1: Harm-benefit ratios for off-label drugs with different efficacy and safety profiles across case fatality ratios. Note: The depicted harm-
benefit ratios for off-label drugs indicate the ratio between harms (i.e. serious adverse events and death due to an off-label treatment) and
benefits (i.e. reduced infection-related mortality due to an off-label treatment). An off-label drug with a harm-benefit ratio <1.0 indicates a net
beneficial effect for the given patient population with a specific baseline case fatality ratio. A rate ratio of <1.0 indicates a protective effect of
the off-label drug. CFR = case fatality ratio; RR = rate ratio; SAE = serious adverse event
several key principles. We believe that off-label treatment
decisions need to be based on (i) clearly defined selec-
tion and treatment criteria, (ii) a strong biological rationale
based on data from in vitro and animal studies (e.g., antivi-
ral activity, reduction of cytokine storm), (iii) a critical ap-
praisal of prior evidence on the efficacy, effectiveness and
safety profile of the off-label drug for similar indications
and patient populations, and (iv) the estimated harm-ben-
efit ratio. This strategy should be followed within a large,
collaborative study setting to accrue experimental evidence
as fast as possible in adequately designed and powered
randomised controlled trials. Digital innovations and the
increased availability of continuously updated electronic
medical records and large learning health systems have
the potential to facilitate evaluating many off-label treat-
ments options as part of pragmatic clinical trials [4]. Nev-
ertheless, waiting for conclusive trial results during health
emergencies could mean withholding potentially effective
off-label treatments from most severely ill patients in the
exponential phase of a pandemic, which may turn out later
to have been the correct or wrong decision. This can be
especially problematic during pandemics, as most studies
performed in the initial epidemic phase may be underpow-
ered, not coordinated at an international level and poor-
ly conducted. In a previous investigation that included 25
head-to-head treatment comparisons with 153 randomised
controlled trials and 24,592 patients, off-label treatments
were not reliably better or worse than approved drug treat-
ments [5]: This general example underscores the impor-
tance of diverse randomised comparisons to detect effec-
tive off-label treatments among many possible candidates.
The COVID-19 pandemic has resulted in a tremendous up-
surge in collaborative research activities to study novel di-
agnostic, prevention and treatment strategies, and to eval-
uate off-label treatments (covid-evidence.org). We should
be cautious, carefully assess and not systematically over-
or underestimate the potential harms and benefits associ-
ated with off-label treatments during international emer-
gencies. Importantly, the well-established drug approval
processes should not be “bypassed” but healthcare profes-
sionals need better guidance and frameworks to rapidly de-
ploy, study and compare off-label treatments under con-
trolled conditions during future international health
emergencies – for instance as part of large-scale factorial
trials with pragmatic and adaptive components. These de-
cisions for or against off-label treatment need to be based
on clearly defined selection and treatment criteria, a strong
biological rationale, a critical appraisal of prior evidence,
and the estimated harm-benefit ratio. The global research
community has acted very dynamically during the initial
phase of the COVID-19 pandemic and we should critically
reflect how to make best use of collaborative research ef-
forts and specifically clinical trials.
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